Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply
- PMID: 35429032
- DOI: 10.1111/apt.16917
Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply
Comment on
-
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.Aliment Pharmacol Ther. 2022 May;55(10):1311-1319. doi: 10.1111/apt.16816. Epub 2022 Feb 15. Aliment Pharmacol Ther. 2022. PMID: 35166374 Free PMC article.
Similar articles
-
Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?Aliment Pharmacol Ther. 2022 May;55(9):1218-1219. doi: 10.1111/apt.16909. Aliment Pharmacol Ther. 2022. PMID: 35429038 No abstract available.
-
Editorial: Tong-Xie-Yao-Fang (TXYF) for irritable bowel syndrome with diarrhoea (IBS-D)-ancient medicine meets modern study. Authors' reply.Aliment Pharmacol Ther. 2018 Aug;48(4):486-487. doi: 10.1111/apt.14906. Aliment Pharmacol Ther. 2018. PMID: 30588696 No abstract available.
-
Editorial: understanding IBS pathophysiology through "converging channels" of research-authors' reply.Aliment Pharmacol Ther. 2021 Nov;54(9):1215-1216. doi: 10.1111/apt.16613. Aliment Pharmacol Ther. 2021. PMID: 34637534 No abstract available.
-
Biofeedback for treatment of irritable bowel syndrome.Cochrane Database Syst Rev. 2019 Nov 12;2019(11):CD012530. doi: 10.1002/14651858.CD012530.pub2. Cochrane Database Syst Rev. 2019. PMID: 31713856 Free PMC article.
-
Recent advances in pharmacological treatment of irritable bowel syndrome.World J Gastroenterol. 2014 Jul 21;20(27):8867-85. doi: 10.3748/wjg.v20.i27.8867. World J Gastroenterol. 2014. PMID: 25083060 Free PMC article. Review.
References
REFERENCES
-
- Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2022. https://doi.org/10.1111/apt.16816
-
- Quigley EM. Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Aliment Pharmacol Ther. 2022;55:1218-9.
-
- Black CJ, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol. 2020;18(2):392-8 e2.
-
- Goodoory VC, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Natural history and disease impact of Rome IV versus Rome III irritable bowel syndrome: a longitudinal follow-up study. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.04.043
-
- Shivaji UN, Ford AC. Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. Prim Health Care Res Dev. 2015;16(3):263-9.